Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Perry Pratt

Internal Medicine Middletown, CT Medical Doctor

NPI 1952712721 CMS profile 4212368

410 Saybrook Rd Ste 201, Middletown, CT 06457

Open in the dashboard

General payments

$6,091

286 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Perry Pratt of Middletown, CT is reported in the CMS Open Payments database as having received $6,091 across 286 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $330 17
2024 General $1,312 65
2023 General $1,669 79
2022 General $1,968 87
2021 General $681 36
2019 General $131 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Perry Pratt
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Perry Pratt were reported at $330. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Perry Pratt Internal Medicine median Middle half National median
2019 $131 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $681 $135 $37–$521 $132
2022 $1,968 $141 $42–$496 $149
2023 $1,669 $149 $45–$519 $160
2024 $1,312 $154 $47–$537 $164
2025 $330 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,360 77 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $990 52 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $763 31 payments
  4. Ardelyx, Inc. $375 18 payments
  5. Celgene Corporation $314 14 payments
  6. QOL Medical, LLC $292 12 payments
  7. Pfizer Inc. $253 8 payments
  8. Regeneron Healthcare Solutions, Inc. $196 8 payments
  9. Intercept Pharmaceuticals, Inc. $167 9 payments
  10. Janssen Biotech, Inc. $142 6 payments
  11. Other $1,240 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,986 284 payments
  2. Long term medical supply or device loan $82 1 payment
  3. Education $23 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $772 35 payments
  2. ENTYVIO $685 27 payments
  3. SKYRIZI $553 29 payments
  4. RINVOQ $459 27 payments
  5. IBSRELA $375 18 payments
  6. LINZESS $346 25 payments
  7. CREON $327 22 payments
  8. ZEPOSIA $308 14 payments
  9. XELJANZ $253 8 payments
  10. TRULANCE $218 17 payments
  11. Other $2,718 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

986

Median for Gastroenterology: 569

Drug cost

$178,878

Median for Gastroenterology: $104,976

Branded share of claims

19.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 26 $63,226
Creon Lipase/Protease/Amylase Brand 12 $54,915
Linzess Linaclotide Brand 30 $27,609
Esomeprazole Magnesium Generic 165 $8,693
Dexlansoprazole Dr Dexlansoprazole Brand 13 $5,579
Omeprazole Generic 203 $4,226
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 30 $4,222
Pantoprazole Sodium Generic 136 $3,043
Famotidine Generic 160 $2,689
Lansoprazole Generic 26 $1,057

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$84,131

Medicare's payments for the services billed

Medicare patients

208

Average age 74

Services billed

2,094

115 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 41%
Ischemic heart disease 35%
Depression 28%
Diabetes 27%
Atrial fibrillation 25%
Chronic kidney disease 23%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBSRELA
  • Ardelyx, Inc. $149
$149 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $139
$139 26 —
SKYRIZI
  • AbbVie, Inc. $134
$134 — —
RINVOQ
  • AbbVie, Inc. $111
$111 — —
ZEPOSIA
  • Celgene Corporation $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

286 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record